DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

The purpose of this study is to determine the feasibility of administering DL-alpha-difluoromethylornithine (DFMO) to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.

Trial Details

NCT ID
NCT06892678
Phase
PHASE1 / PHASE2
Sponsor
Montefiore Medical Center
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • DFMO
Locations (sample)
  • The Bronx, New York, United States|40.84985,-73.86641

Key Eligibility Criteria

  • Patients \< 40 years of age at the time of enrollment
  • Diagnosis of relapsed osteosarcoma or relapsed Ewing sarcoma who have completed all planned therapy for their relapse, as described in the protocol…
  • Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2
  • Myelosuppressive chemotherapy: At least 14 days must have elapsed since completion of myelosuppressive therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →